Table 2 Progression-free survival (PFS) and overall survival (OS) according to age categories and chemotherapy backbone regimens
Chemotherapy regimen | <65 years | 65-75 years | ≥75 years | |
|---|---|---|---|---|
FOLFOX | n | 903 | 394 | 51 |
Median PFS (95% CI) | 11.2 (10.3-12.0) | 12.1 (10.9-13.4) | 11.8 (8.9-14.7) | |
Median OS (95% CI) | 25.5 (22.8-28.1) | 30.7 (27.6-33.7) | not reached | |
XELOX | n | 753 | 313 | 25 |
Median PFS (95% CI) | 11.5 (10.6-12.5) | 11.5 (10.3-12.8) | 13.2 (10.9-15.5) | |
Median OS (95% CI) | 30.0 (27.3-32.7) | 27.0 (23.8-30.2) | 25.1 (16.6-33.6) | |
FOLFIRI | n | 199 | 74 | 5 |
Median PFS (95% CI) | 12.2 (10.7-13.8) | 11.3 (9.0-13.6) | - | |
Median OS (95% CI) | 25.4 (21.5-29.4) | 22.9 (19.9-25.9) | - | |
XELIRI | n | 127 | 39 | 1 |
Median PFS (95% CI) | 14.9 (12.5-17.2) | 11.3 (8.4-14.1) | - | |
Median OS (95% CI) | 29.1 (22.4-35.9) | 26.7 (19.9-33.6) | - | |
Capecitabine | n | 39 | 44 | 18 |
Median PFS (95% CI) | 9.4 (6.1-12.7) | 10.3 (4.1-16.5) | 13.4 (7.9-18.8) | |
Median OS (95% CI) | 31.1 (27.0-35.2) | 17.0 (6.3-27.7) | 19.8 (11.8-27.9) | |
5-FU/LV | n | 21 | 21 | 23 |
Median PFS (95% CI) | 10.1 (4.1-16.1) | 5.9 (3.3-8.5) | 10.5 (6.9-14.0) | |
Median OS (95% CI) | 22.6 (14.0-31.2) | 21.3 (5.4-37.1) | 19.4 (10.7-28.2) |